Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL
Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-120659
- Despite improved survival in the Rituximab (R) era, a considerable number of patients with diffuse large B-cell lymphoma (DLBCL) ultimately die from the disease. Functional imaging using [18F]fluorodeoxyglucose-PET is suggested for assessment of residual viable tumor very early during treatment but is compromised by non-specific tracer retention in inflammatory lesions. The PET tracer [18F]fluorodeoxythymidine (FLT) as surrogate marker of tumor proliferation may overcome this limitation. We present results of a prospective clinical studyDespite improved survival in the Rituximab (R) era, a considerable number of patients with diffuse large B-cell lymphoma (DLBCL) ultimately die from the disease. Functional imaging using [18F]fluorodeoxyglucose-PET is suggested for assessment of residual viable tumor very early during treatment but is compromised by non-specific tracer retention in inflammatory lesions. The PET tracer [18F]fluorodeoxythymidine (FLT) as surrogate marker of tumor proliferation may overcome this limitation. We present results of a prospective clinical study testing FLT-PET as superior and early predictor of response to chemotherapy and outcome in DLBCL. 54 patients underwent FLT-PET prior to and one week after the start of R-CHOP chemotherapy. Repetitive FLT-PET imaging was readily implemented into the diagnostic work-up. Our data demonstrate that the reduction of FLT standard uptake valuemean (SUVmean) and SUVmax one week after chemotherapy was significantly higher in patients achieving complete response (CR, n=48; non-CR, n=6; p<0.006). Martingale-residual and Cox proportional hazard analyses showed a significant monotonous decrease of mortality risk with increasing change in SUV. Consistent with these results, early FLT-PET response showed relevant discriminative ability in predicting CR. In conclusion, very early FLT-PET in the course of R-CHOP chemotherapy is feasible and enables identification of patients at risk for treatment failure.…
Autor(en): | Ken Herrmann, Andreas K. Buck, Tibor Schuster, Kathrin Abbrederis, Christina Blümel, Ivan Santi, Martina Rudelius, Hans-Jürgen Wester, Christian Peschel, Markus Schwaiger, Tobias Dechow, Ulrich Keller |
---|---|
URN: | urn:nbn:de:bvb:20-opus-120659 |
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
Institute der Universität: | Medizinische Fakultät / Klinik und Poliklinik für Nuklearmedizin |
Medizinische Fakultät / Pathologisches Institut | |
Sprache der Veröffentlichung: | Englisch |
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | Oncotarget |
ISSN: | 1949-2553 |
Erscheinungsjahr: | 2014 |
Band / Jahrgang: | 5 |
Heft / Ausgabe: | 12 |
Seitenangabe: | 4050-59 |
Originalveröffentlichung / Quelle: | Oncotarget, Vol. 5, No. 12, 4050-59 |
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Freie Schlagwort(e): | DLBCL; FLT-PET; [18F]Fluorodeoxythymidine; lymphoma; positron emission tomography |
Datum der Freischaltung: | 12.02.2016 |
Lizenz (Deutsch): | CC BY: Creative-Commons-Lizenz: Namensnennung |